vTv Therapeutics Reports Second Quarter 2025 Financial Results and Provides Corporate Update

Rhea-AI Summary

vTv Therapeutics (Nasdaq: VTVT) reported Q2 2025 financial results and key developments in its cadisegliatin program for type 1 diabetes treatment. The company announced the first patient randomization in its Phase 3 CATT1 trial, with topline data expected in H2 2026. Financial results showed a net loss of $6.0 million ($0.92 per share) compared to $5.2 million ($0.81 per share) in Q2 2024.

The company's cash position stood at $25.9 million as of June 30, 2025, down from $36.7 million at year-end 2024. R&D expenses increased to $4.1 million from $3.4 million year-over-year, while G&A expenses slightly decreased to $3.6 million. Notable developments include strengthening intellectual property with a new patent allowance through 2041 and the appointment of Michael Tung as CFO.

Positive

• First patient randomized in Phase 3 CATT1 trial for cadisegliatin, advancing clinical development
• New patent allowance for crystalline salt form of cadisegliatin extending protection through 2041
• Strengthened leadership team with appointment of experienced CFO Michael Tung
• Maintained strong cash position of $25.9 million

Negative

• Net loss increased to $6.0 million in Q2 2025 from $5.2 million in Q2 2024
• Cash position decreased by $10.8 million since December 2024
• R&D expenses increased by 20.6% year-over-year
• No revenue generated in Q2 2025

Insights

Biotechnology Research Analyst

vTv's advancing its Phase 3 diabetes drug amid increasing cash burn; pipeline shows promise but financials warrant caution.

vTv Therapeutics has reached a significant clinical milestone with the randomization of the first participant in their Phase 3 CATT1 trial for cadisegliatin in type 1 diabetes. This GKA (glucokinase activator) represents a potentially first-in-class oral adjunctive therapy to insulin with a differentiated liver-selective mechanism that could address the critical unmet need of hypoglycemia management.

The company's cash position of $25.9 million represents a concerning 29.4% decline from $36.7 million at year-end 2024, giving them approximately 12-15 months of runway at current burn rates. R&D expenses increased to $4.1 million from $3.4 million year-over-year, primarily due to higher payroll costs rather than increased clinical activity.

The net loss widened to $6.0 million ($0.92 per share) compared to $5.2 million ($0.81 per share) in Q2 2024, indicating accelerating cash consumption as they advance their lead program. The recently allowed patent extending protection until 2041 for crystalline salt forms of cadisegliatin significantly strengthens their intellectual property position.

With topline Phase 3 data expected in H2 2026, vTv faces the challenging task of managing their cash runway through this critical clinical readout period. The appointment of Michael Tung as CFO brings valuable financial management experience at a crucial time. While cadisegliatin represents a potential breakthrough for diabetes management, investors should monitor the company's ability to fund operations through their clinical development timeline without significant dilution.

•   First study participant randomized in Phase 3 CATT1 trial evaluating cadisegliatin for the treatment of type 1 diabetes with data expected in second half of 2026

•   Cadisegliatin intellectual property portfolio expanded

•   Leadership team strengthened

HIGH POINT, N.C., Aug. 12, 2025 (GLOBE NEWSWIRE) -- vTv Therapeutics Inc. (Nasdaq: VTVT), a late-stage biopharmaceutical company focused on the development of cadisegliatin, a potential first-in-class oral adjunctive therapy to insulin being investigated for the treatment of type 1 diabetes (T1D), today reported financial results for the second quarter ended June 30, 2025, and provided an update on recent corporate developments.

“The randomization of the first participant in our CATT1 Phase 3 trial earlier this month reflects our continued momentum in advancing cadisegliatin,” said Paul Sekhri, Chairman, President and CEO of vTv Therapeutics. “Cadisegliatin is designed to selectively activate glucokinase in the liver, a differentiated approach that may improve glycemic control and reduce the risk of hypoglycemia when used alongside insulin. Hypoglycemic episodes remain frequent, life-disruptive, and sometimes life-threatening for people with type 1 diabetes. We believe cadisegliatin could play a meaningful role in addressing this large unmet medical need.”

Recent Company Highlights

• First Study Participant Randomized in Cadisegliatin Phase 3 Trial. In August 2025, vTv Therapeutics announced that the first study participant was randomized in the Company’s CATT1 Phase 3 Trial evaluating cadisegliatin as an adjunctive therapy to insulin for the treatment of T1D. Topline data from the study is expected in the second half of 2026. (link to press release)

• Patent Allowance for Crystalline Salt Form of Cadisegliatin. In August 2025, the United States Patent and Trademark Office allowed claims for a patent application directed to compositions of matter of crystalline forms of salts and co-crystals of cadisegliatin. The patent term runs through 2041. (link to press release)

• Corporate Presentation at HCW@Home. In June 2025, the Company participated in a virtual fireside chat as part of the H.C. Wainwright HCW@Home series. (link to webcast replay)

• Appointment of Chief Financial Officer. In May 2025, vTv Therapeutics appointed Michael Tung, MD, MBA, as Chief Financial Officer. Dr. Tung brings over 20 years of financial management, investment experience, and strategic leadership across both private and public life sciences companies. (link to press release)
  
  

Second Quarter 2025 Financial Results

• Cash Position: The Company’s cash position as of June 30, 2025, was $25.9 million compared to $36.7 million as of December 31, 2024.

• Research & Development (R&D) Expenses: R&D expenses were $4.1 million and $3.4 million in each of the three months ended June 30, 2025, and 2024, respectively. The increase reflects higher indirect costs primarily related to payroll expenses. This was partially offset by lower spending on cadisegliatin and other projects.

• General & Administrative (G&A) Expenses: G&A expenses were $3.6 million and $3.7 million for each of the three months ended June 30, 2025, and 2024, respectively. The decrease was primarily due to decreases in other operating costs. This was partially offset by an increase in payroll related costs.

• Other Income, Net: Other income for the three months ended June 30, 2025, was immaterial. Other income for the three months ended June 30, 2024, was $0.2 million and was driven by gains related to the change in the fair value of the outstanding warrants to purchase shares of our own stock issued to related parties.

• Net Loss: Net loss attributable to vTv shareholders for the three months ended June 30, 2025, was $6.0 million or $0.92 per basic share. Net loss attributable to vTv shareholders for the comparable period a year ago was $5.2 million or $0.81 per basic share.
  
  

vTv Therapeutics Inc. Condensed Consolidated Balance Sheets (in thousands)
		June 30, 2025				December 31, 2024
		(Unaudited)
Assets
Current assets:
Cash and cash equivalents		$	25,922			$	36,746
Prepaid expenses			359				1,192
Other current assets			93				175
Total current assets			26,374				38,113
Property and equipment, net			16				28
Operating lease right-of-use assets			58				125
Total assets		$	26,448			$	38,266
Liabilities and Stockholders’ Equity
Current liabilities:
Accounts payable and accrued expenses		$	5,216			$	5,027
Current portion of operating lease liabilities			79				169
Total current liabilities			5,295				5,196
Contract liabilities, net of current portion			18,669				18,669
Warrant liability, related party			31				57
Warrant liability			48				43
Total liabilities			24,043				23,965
Commitments and contingencies
Stockholders’ equity:
Class A Common Stock			26				26
Class B Common Stock			6				6
Additional paid-in capital			313,586				311,885
Accumulated deficit			(310,856	)			(299,718	)
Total stockholders’ equity attributable to vTv Therapeutics Inc.			2,762				12,199
Noncontrolling interest			(357	)			2,102
Total stockholders’ equity			2,405				14,301
Total liabilities and stockholders’ equity		$	26,448			$	38,266

vTv Therapeutics Inc. Condensed Consolidated Statements of Operations (in thousands, except per share data)
		Three Months Ended June 30,								Six Months Ended June 30,
			2025				2024				2025				2024
		(Unaudited)								(Unaudited)
Revenue		$	—			$	—			$	—			$	1,000
Operating expenses:
Research and development			4,103				3,439				6,933				6,088
General and administrative			3,618				3,716				7,291				7,694
Total operating expenses			7,721				7,155				14,224				13,782
Operating loss			(7,721	)			(7,155	)			(14,224	)			(12,782	)
Interest income			275				553				606				632
Other income (expense), net			66				193				21				(178	)
Loss before income taxes and noncontrolling interest			(7,380	)			(6,409	)			(13,597	)			(12,328	)
Income tax provision			—				—				—				100
Net loss before noncontrolling interest			(7,380	)			(6,409	)			(13,597	)			(12,428	)
Less: net loss attributable to noncontrolling interest			(1,334	)			(1,229	)			(2,459	)			(2,383	)
Net loss attributable to vTv Therapeutics Inc.		$	(6,046	)		$	(5,180	)		$	(11,138	)		$	(10,045	)
Net loss attributable to vTv Therapeutics Inc. common shareholders		$	(6,046	)		$	(5,180	)		$	(11,138	)		$	(10,045	)
Net loss per share of vTv Therapeutics Inc. Class A common stock, basic and diluted		$	(0.92	)		$	(0.81	)		$	(1.69	)		$	(1.97	)
Weighted average number of vTv Therapeutics Inc. Class A common stock, basic and diluted			6,587,070				6,403,444				6,584,969				5,098,877

About Cadisegliatin

Cadisegliatin (TTP399) is a novel, oral small molecule, liver-selective glucokinase activator being investigated as a potential first-in-class oral adjunctive treatment for type 1 diabetes (T1D). In non-clinical studies, cadisegliatin, acting selectively on the liver, increased the activity of glucokinase independently from insulin which supports clinical investigation of improvement in glycemic control through hepatic glucose uptake and glycogen storage.

Cadisegliatin is under investigation and the safety and efficacy have not been established. There is no guarantee that this product will receive health authority approval or become commercially available for the use being investigated.

About vTv Therapeutics

vTv Therapeutics is a late-stage biopharmaceutical company focused on developing oral, small molecule drug candidates intended to help treat people living with diabetes and other chronic diseases. vTv’s clinical pipeline is led by cadisegliatin, currently in a Phase 3 trial, a potential first-in-class oral glucokinase activator being investigated for the treatment of type 1 diabetes. vTv and its development partners are investigating multiple molecules across different indications for chronic diseases. Learn more at vtvtherapeutics.com or follow the company on LinkedIn or X.

Forward-Looking Statement

This release contains forward-looking statements, which involve risks and uncertainties. These forward-looking statements can be identified by the use of forward-looking terminology, including the terms “anticipate,” “believe,” “could,” “estimate,” “expect,” “intend,” “may,” “plan,” “potential,” “predict,” “project,” “should,” “target,” “will,” “would” and, in each case, their negative or other various or comparable terminology. All statements other than statements of historical facts contained in this release, including statements regarding the timing of our clinical trials, our strategy, future operations, future financial position, future revenue, projected costs, prospects, plans, objectives of management and expected market growth are forward-looking statements. These statements involve known and unknown risks, uncertainties and other important factors that may cause our actual results, performance, or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements. Important factors that could cause our results to vary from expectations include those described under the heading “Risk Factors” in our Annual Report on Form 10-K and our other filings with the SEC. These forward-looking statements reflect our views with respect to future events as of the date of this release and are based on assumptions and subject to risks and uncertainties. Given these uncertainties, you should not place undue reliance on these forward-looking statements. These forward-looking statements represent our estimates and assumptions only as of the date of this release and, except as required by law, we undertake no obligation to update or review publicly any forward-looking statements, whether as a result of new information, future events or otherwise after the date of this release. We anticipate that subsequent events and developments will cause our views to change. Our forward-looking statements do not reflect the potential impact of any future acquisitions, merger, dispositions, joint ventures, or investments we may undertake. We qualify all our forward-looking statements by these cautionary statements.

Investor Contact
John Fraunces
LifeSci Advisors, LLC
917-355-2395
jfraunces@lifesciadvisors.com

Media Contact
Caren Begun
TellMed Strategies
201-396-8551
caren.begun@tmstrat.com

FAQ

What were vTv Therapeutics (VTVT) Q2 2025 earnings results?

vTv reported a net loss of $6.0 million ($0.92 per share) in Q2 2025, compared to $5.2 million ($0.81 per share) in Q2 2024. The company had no revenue and ended the quarter with $25.9 million in cash.

What is the status of vTv Therapeutics' cadisegliatin Phase 3 trial?

vTv has initiated patient randomization in the Phase 3 CATT1 trial for cadisegliatin as an adjunctive therapy to insulin for type 1 diabetes. Topline data is expected in the second half of 2026.

How much cash does VTVT have and what is their burn rate?

As of June 30, 2025, vTv had $25.9 million in cash, down from $36.7 million at the end of 2024, indicating a cash burn of approximately $10.8 million over six months.

What is cadisegliatin and how does it work?

Cadisegliatin is a novel, oral small molecule that selectively activates glucokinase in the liver. It's being developed as a potential first-in-class oral adjunctive treatment for type 1 diabetes, designed to improve glycemic control and reduce hypoglycemia risk when used with insulin.

What recent intellectual property developments has VTVT announced?

In August 2025, vTv received patent allowance for compositions of crystalline forms of cadisegliatin salts and co-crystals, with patent protection extending through 2041.